- Home
- HAYW vs DNLI Comparison
HAYW vs DNLI Comparison
Compare HAYW & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HAYW | DNLI |
|---|---|---|
| Founded | 1925 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HAYW | DNLI |
|---|---|---|
| Price | $15.10 | $23.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $17.50 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.93 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,122,155,000.00 | N/A |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $5.96 | $408.85 |
| P/E Ratio | $136.36 | ★ N/A |
| Revenue Growth | ★ 6.71 | N/A |
| 52 Week Low | $12.93 | $12.58 |
| 52 Week High | $17.73 | $24.65 |
Technical Indicators
Market Signals| Indicator | HAYW | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 68.02 |
| Support Level | $14.86 | $18.27 |
| Resistance Level | $17.01 | $23.62 |
| Average True Range (ATR) | 0.43 | 1.18 |
| MACD | 0.10 | 0.35 |
| Stochastic Oscillator | 81.27 | 76.67 |
Price Performance
Historical ComparisonAbout HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2025.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.